AOC Development: Conjugation Site Selection, DAR Control & In Vitro Testing | Full Webinar

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

Oligonucleotide therapeutics hold great promise, but extrahepatic delivery remains a challenge. Antibody–oligonucleotide conjugates (AOCs) are emerging as a powerful solution – provided you can master conjugation chemistry, DAR control, analytical characterization, and functional assessment. https://www.youtube.com/watch?v=CNr9ZsU2qrk In this recorded webinar, our experts from Medicilon cover: How conjugation chemistry impacts AOC consistency and developability Why DAR control […]

BioTrinity 2026

Meet Medicilon at BioTrinity 2026

April 14-15, 2026
Convene, 133 Houndsditch, London EC3A 7BX, United Kingdom

Search Medicilon

Meet Medicilon at Nordic PMF 2026

Nordic PMF 2026

Preclinical CRO

AACR 2026 Special Report: An In-Depth Review of Medicilon’s Three Technical Posters | Bilingual

Meet Medicilon at ICDD 2026

ICDD 2026

Contact Medicilon

Name(Required)
Address(Required)